Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • 16 hours ago

New Strong Buy Stocks for August 17th

TAK, VLO, PFX, SBLK and RELY have been added to the Zacks Rank #1 (Strong Buy) List on August 17, 2026.

Zacks Investment Research • 19 hours ago

Best Income Stocks to Buy for August 17th

SBLK, TAK and STBA made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 17, 2026.

Zacks Investment Research • 17 hours ago

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. TAK's Q1 showed 10% revenue growth, but bottom-line weakness from higher taxes and lower operating cash flow due to mounting receivables. Orzeyful's FDA approval is promising, but its commercial impact is likely limited compared to Entyvio; pipeline drugs like zasocitinib offer longer-term potential, but how much is as yet uncertain.

Seeking Alpha • Aug 7, 2026

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.

Benzinga • Aug 6, 2026

US FDA approves Takeda's sleep disorder pill

The FDA has approved Takeda Pharmaceuticals' oral drug for narcolepsy, the U.S. ​health regulator said on Wednesday, backing ‌the first treatment that targets all the symptoms of the rare sleep disorder.

Reuters • Aug 5, 2026

U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to tr.

Business Wire • Aug 5, 2026

Takeda Pharmaceutical Q1 Earnings Call Highlights

Takeda Pharmaceutical NYSE: TAK said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its mature portfolio.

MarketBeat • Jul 30, 2026

Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript

Seeking Alpha • Jul 30, 2026

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter.

Business Wire • Jul 30, 2026